Three Seasons Wealth LLC Buys New Holdings in IDEXX Laboratories, Inc. $IDXX

Three Seasons Wealth LLC bought a new position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 5,126 shares of the company’s stock, valued at approximately $3,275,000. IDEXX Laboratories accounts for 0.3% of Three Seasons Wealth LLC’s investment portfolio, making the stock its 20th biggest holding.

A number of other institutional investors have also recently bought and sold shares of the business. Geode Capital Management LLC raised its stake in shares of IDEXX Laboratories by 2.3% in the 2nd quarter. Geode Capital Management LLC now owns 2,464,290 shares of the company’s stock valued at $1,317,875,000 after buying an additional 54,402 shares in the last quarter. Bank of New York Mellon Corp boosted its position in shares of IDEXX Laboratories by 156.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 1,451,390 shares of the company’s stock valued at $778,439,000 after acquiring an additional 884,808 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of IDEXX Laboratories by 37.0% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,076,429 shares of the company’s stock valued at $452,046,000 after acquiring an additional 290,551 shares in the last quarter. William Blair Investment Management LLC increased its stake in IDEXX Laboratories by 7.5% in the second quarter. William Blair Investment Management LLC now owns 685,088 shares of the company’s stock valued at $367,440,000 after acquiring an additional 47,977 shares during the period. Finally, Legal & General Group Plc raised its position in IDEXX Laboratories by 1.8% in the second quarter. Legal & General Group Plc now owns 648,626 shares of the company’s stock worth $347,884,000 after purchasing an additional 11,768 shares in the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

IDEXX Laboratories Trading Up 0.0%

Shares of IDXX opened at $688.48 on Monday. The company has a debt-to-equity ratio of 0.24, a quick ratio of 0.87 and a current ratio of 1.18. The company has a market cap of $54.98 billion, a price-to-earnings ratio of 54.60, a PEG ratio of 4.11 and a beta of 1.67. The stock has a fifty day moving average price of $695.70 and a two-hundred day moving average price of $632.85. IDEXX Laboratories, Inc. has a 52-week low of $356.14 and a 52-week high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Monday, November 3rd. The company reported $3.22 earnings per share for the quarter, beating analysts’ consensus estimates of $3.14 by $0.08. IDEXX Laboratories had a return on equity of 67.78% and a net margin of 24.65%.The company had revenue of $1.11 billion during the quarter, compared to analyst estimates of $1.07 billion. During the same period last year, the company posted $2.80 earnings per share. The firm’s quarterly revenue was up 13.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. Analysts predict that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

Insiders Place Their Bets

In other IDEXX Laboratories news, EVP Nimrata Hunt sold 9,425 shares of the business’s stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $703.34, for a total value of $6,628,979.50. Following the completion of the transaction, the executive vice president directly owned 21,149 shares of the company’s stock, valued at approximately $14,874,937.66. The trade was a 30.83% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 0.98% of the company’s stock.

Analyst Ratings Changes

IDXX has been the topic of a number of recent research reports. BTIG Research lifted their price objective on IDEXX Laboratories from $785.00 to $830.00 and gave the company a “buy” rating in a report on Tuesday, November 4th. UBS Group boosted their price target on IDEXX Laboratories from $710.00 to $750.00 and gave the company a “neutral” rating in a research note on Tuesday, November 4th. Jefferies Financial Group reiterated a “buy” rating and set a $830.00 price objective on shares of IDEXX Laboratories in a research note on Tuesday, November 4th. Stifel Nicolaus set a $775.00 price objective on IDEXX Laboratories in a report on Monday, November 3rd. Finally, Wall Street Zen lowered shares of IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a report on Saturday, November 29th. Seven equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $763.50.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.